Among these approaches, as shown in Table 1, TIGIT-Ig protein, agonistic anti-TIGIT antibodies, and TIM-3 ligands (e.g., galectin-9), along with PD-L1-Ig and CTLA4-Ig proteins, should be considered candidates for development as bench-to-bedside therapeutics for treatment of T-cell-mediated autoimmune glomerulonephritis through regulation of the function of Th1/Th17 and Treg cells. Here, TIGIT is linked to autoimmune glomerulonephritis.